Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (PURPOSE 2)

Gilead Sciences

Status and phase: Active, not recruiting; Phase 3

Conditions: Pre-Exposure Prophylaxis of HIV Infection

Treatments: Drug: PTM F/TDF; Drug: Placebo SC LEN; Drug: Oral Lenacapavir (LEN); Drug: F/TDF; Drug: PTM Oral LEN; Drug: Sub-cutaneous (SC) Lenacapavir (LEN); Drug: F/TAF (for US participants only)

Study type: Interventional

Funder types: Industry

Identifiers

NCT04925752

GS-US-528-9023

DOH-27-102021-6681 (Other Identifier)

Details and patient eligibility

About

The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.

Enrollment: 3,295 patients

Sex: All

Ages: 16+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

Incidence Phase

• CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.

• HIV-1 status unknown at screening and no prior HIV-1 testing within the last 3 months.

• Sexually active with ≥ 1 partner assigned male at birth (condomless receptive anal sex) in the last 12 months and 1 of the following:

  • Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks.
  • History of syphilis, rectal gonorrhea, or rectal chlamydia in the last 24 weeks.
  • Self-reported use of stimulants with sex in the last 12 weeks.

Randomized Phase

• Negative local rapid fourth generation HIV-1/2 Ab/Ag, central fourth generation HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT).
• Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min at screening according to the Cockcroft-Gault formula for creatinine clearance (CLcr).

Key Exclusion Criteria:

Incidence Phase

• Prior use of HIV PrEP (including F/TDF or F/TAF) or HIV postexposure prophylaxis (PEP) in the past 12 weeks or any prior use of long-acting systemic PrEP (including cabotegravir or islatravir).
• Prior recipient of an HIV vaccine or HIV broadly neutralizing antibody formulation.

Randomized Phase

• Acute viral hepatitis A, B or C or evidence of chronic hepatitis B or C infection.
• Severe hepatic impairment or a history of or current clinical decompensated liver cirrhosis.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

3,295 participants in 4 patient groups

Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF

Experimental group

Description:

Participants will receive the following for at least 52 weeks: * Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks * Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily * Oral LEN 600 mg on Days 1 and 2 Participants will receive oral LEN if SC injections are not available

Treatment:

Drug: Sub-cutaneous (SC) Lenacapavir (LEN)

Drug: Oral Lenacapavir (LEN)

Drug: PTM F/TDF

Blinded Phase: Placebo LEN + F/TDF

Experimental group

Description:

Participants will receive the following for at least 52 weeks: * SC LEN placebo every 26 weeks * Oral F/TDF 200/300 mg once daily * PTM Oral LEN on Days 1 and 2 Participants will receive oral LEN placebo if SC injections are not available

Treatment:

Drug: PTM Oral LEN

Drug: F/TDF

Drug: Placebo SC LEN

LEN Open-Label Extension (OLE) Phase

Experimental group

Description:

After completion of the Blinded phase, participants will be offered entry into the LEN OLE Phase. Participants randomized to LEN will continue to receive SC LEN 927 mg every 26 weeks for a total of 2 doses. Participants randomized to F/TDF will receive SC LEN 927 mg on OLE Day 1, OLE Week 26, and will also receive oral LEN 600 mg on OLE Days 1 and 2.

Treatment:

Drug: Sub-cutaneous (SC) Lenacapavir (LEN)

Drug: Oral Lenacapavir (LEN)

PK Tail Phase

Experimental group

Description:

At the completion of the LEN OLE phase, participants will transition into the PK Tail phase. Additionally, participants that prematurely discontinue the study drug during blinded phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase are also eligible to transition to the PK Tail Phase. Participants will receive oral F/TDF (or Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only) once daily for 78 weeks beginning 26 weeks after the last injection of LEN.

Treatment:

Drug: F/TAF (for US participants only)

Drug: F/TDF